Table 5.
Variable |
All patients (n = 144) |
Matched patients (n = 72) |
||
Hazard ratio | P value | Hazard ratio | P value | |
Age: < 60 yr vs ≥ 60 yr | 1.248 (0.669-2.330) | 0.486 | 0.778 (0.308-1.965) | 0.595 |
Sex: Male vs female | 0.991 (0.525-1.869) | 0.977 | 0.974 (0.432-2.194) | 0.949 |
Comorbidity: Present vs absent | 1.228 (0.664-2.271) | 0.513 | 1.830 (0.782-4.281) | 0.163 |
NAC: Yes vs No | 1.466 (0.777-2.768) | 0.235 | 1.709 (0.756-3.816) | 0.192 |
Extent of gastrectomy: Subtotal vs total | 1.394 (0.966-1.883) | 0.079 | 1.282 (0.479-3.435) | 0.621 |
Tumor location: Lower vs upper | 1.128 (0.507-2.514) | 0.767 | 0.676 (0.218-2.522) | 0.676 |
Tumor location: Middle vs upper | 1.750 (0.758-3.832) | 0.197 | 0.758 (0.228-2.522) | 0.651 |
Tumor size: > 5 cm vs ≤ 5 cm | 2.429 (1.282-4.603) | 0.006 | 4.765 (1.886-12.038) | 0.001 |
cT stage: T4a/4b vs T3 | 0.834 (0.461-1.570) | 0.548 | 1.347 (0.575-3.153) | 0.492 |
cN stage: N1-3 vs N0 | 1.748 (0.839-3.641) | 0.136 | 0.971 (0.332-2.844) | 0.957 |
Lymphovascular invasion: Yes vs No | 2.291 (1.233-4.256) | 0.009 | 2.600 (1.141-5.928) | 0.023 |
Neural invasion: Yes vs No | 1.390 (0.736-2.652) | 0.310 | 2.304 (0.953-5.567) | 0.064 |
Adjuvant chemotherapy: Yes vs No | 0.673 (0.357-1.270) | 0.222 | 0.654 (0.271-1.581) | 0.346 |
NAC: Neoadjuvant chemotherapy.